BIO Double Helix Sponsor
Sponsors

Company Profile

Mithridion, Inc

Drug Development
Neurology
CNS

505 Science Drive
Suite C
Madison, WI 53711
USA
www.mithridion.com 		Incorporated in 2004
12 Employees 		Privately Held

This Year's Highlights

  • Raised $2.2 million in angel and venture capital, plus NIH SBIR and STTR grants ($297k), WI State Loan ($200k), instrument lease ($160k), and Grand Prize, WI Governor's Business Plan Contest($100k).
  • Built powerful capability around a new LC-triple quad mass spectrometry system to evaluate blood-brain barrier penetration, pharmacokinetics and drug metabolism
  • Developed 4 new drug lead series; focused on one lead series for parenteral or oral delivery of drug to the brain

Anticipated Highlights

  • Aiming to select a drug development candidate by end 3Q 2007
  • Targeting financing for formal drug development 4Q/2007 - 1Q/2008
  • Aiming to add new drug development projects in 2008 to increase the breadth and depth of Mithridion's product pipeline

Corporate Mission

Mithridion aims to build a preeminent CNS-focused pharmaceutical company. We aim to be one of the first companies to develop effective drugs to slow down or halt disease processes in common neurodegenerative diseases. Mithridion?s initial focus is on meeting the enormous unmet clinical needs of an estimated 4.5m Americans and 12m people worldwide with Alzheimer?s disease (AD), potentially a $10bn market opportunity. Mithridion is developing disease-modifying drugs for AD, based on its novel proprietary technology, including advanced small molecule drug leads.